Physician profile
Richa Sood
NPI 1235598228
$4,425.07
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $901 · 2022: $1,391 · 2023: $1,852 · 2024: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,127 · Education: $6.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,127.18 |
| Education | $6.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,670.53 | 2021-2024 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $556.74 | 2021-2023 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $460.77 | 2021-2024 | Dupixent |
| Pfizer INC. | $208.99 | 2021-2023 | |
| Pharming Healthcare, INC. | $175.49 | 2021-2024 | Ruconest |
| Kaleo, INC. | $171.81 | 2021-2023 | Auvi-Q |
| Aimmune Therapeutics, INC. | $164.86 | 2021-2023 | |
| Abbvie INC. | $148.87 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $138.43 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $130.65 | 2022-2023 | Cuvitru, Takhzyro |
| Genzyme Corporation | $114.16 | 2021-2023 | |
| Csl Behring | $98.13 | 2022-2023 | Haegarda |
| Novartis Pharmaceuticals Corporation | $87.56 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $65.37 | 2021 | |
| Grifols USA, LLC | $60.39 | 2023-2024 | Prolastin-C Liquid, Xembify |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $38.92 | 2022-2023 | Orladeyo |
| Blueprint Medicines Corporation | $36.02 | 2021-2022 | |
| Amgen INC. | $26.63 | 2023 | Tezspire |
| Covis Pharma Gmbh | $24.02 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.03 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.66 | 2021 | |
| Optinose US, INC. | $14.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richa Sood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.